SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL™ platform. These patents extend AnaptysBio’s leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.
